|  | Collecting Quality Data in Psychiatric Trials Understanding interactions among the many factors that give rise to mental illness is a complex task. Learn how to identify and mitigate these elements early on to help ensure trial data accurately captures your compound’s safety and efficacy potential. Premier Research. Built for BiotechSM |
Today's Rundown Featured Story | | | Friday, April 3, 2020 GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine. |
|
|---|
|
Top Stories Friday, April 3, 2020 Two German biotech companies at the start of a race to create new vaccines against the COVID-19 pandemic are warning the EMA and FDA they will need traditional clinical trial hurdles removed if governments want the inoculations as quickly as possible. Friday, April 3, 2020 The COVID-19 pandemic may be disrupting clinical trials and drug launches, but it’s not holding up venture firms intent on bankrolling innovative biotech startups. With Arch Venture Partners, Flagship Pioneering and now venBio unveiling their latest efforts, it looks like everyone’s raising a life sciences fund this week. Friday, April 3, 2020 The new coronavirus has injected all kinds of uncertainty into the biotech world, leading companies to delay clinical trials, reorganize their pipelines and hold off on their IPOs. Not so for Zentalis Pharmaceuticals, which priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March. Friday, April 3, 2020 Horizon Therapeutics has added to its growing acquisitive pipeline with the buyout of Curzion Pharmaceuticals for just $45 million. Friday, April 3, 2020 Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies. The deal, which features $3 billion in milestones, tasks Fate with using its induced pluripotent stem cell (iPSC) platform to develop drugs based on four targets picked out by J&J. Thursday, April 2, 2020 BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test. Thursday, April 2, 2020 Researchers at the University of Pittsburgh School of Medicine developed a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity and that can be delivered into the skin with a Band-Aid-like patch. They're planning to apply to the FDA for approval to start clinical trials soon. Thursday, April 2, 2020 In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K. Friday, April 3, 2020 The White House is pressuring the FDA to allow Fujifilm's Avigan for emergency use against COVID-19. Aurobindo and Novartis terminated their U.S. generics deal on FTC delay. China's API supply so far this year has dropped 10% to 20% on average but is recovering. And more. Friday, April 3, 2020 Vertex moves Kewalramani into CEO post; Pfizer taps Gates Foundation head to board; Sera taps Moyes as CFO. Resources Sponsored by: Applied BioMath Learn how we used a tiered model-based approach of a bispecific antibody to appropriately cover multiple antigen pairs to help teams with informed antibody design, prioritization of experiments, and triaging of challenging antigen pairs Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Outer Edge Technology To survive in these challenging conditions, companies need to promptly address business continuity issues - especially the remote delivery of data and voice solutions. See how Outer Edge can help. Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. | 
